OncoMatch/Clinical Trials/NCT03919552

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Is NCT03919552 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Docetaxel,Carboplatin and Docetaxel,Cisplatin for cisplatin.

Phase 3RecruitingNanfang Hospital, Southern Medical UniversityNCT03919552Data as of Jun 2026Location: China

Treatment: Docetaxel,Carboplatin · Docetaxel,Cisplatin — The purpose of this study is to compare cisplatin-based with carboplatin-based chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to confirm the value of carboplatin-based chemoradiotherapy in NPC patients.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

Docetaxel,CarboplatinDocetaxel,Cisplatin

Disease stage

Required: Stage T3-4NX, TXN2-3 (8th American Joint Commission on Cancer edition)

Tumor staged as T3-4Nx/TxN2-3 (according to the 8th American Joint Commission on Cancer edition). No evidence of distant metastasis (M0).

Demographics

Ages ≤ 64

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: radiotherapy

Exception: except for non-melanomatous skin cancers outside intended RT treatment volume

History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume)

Cannot have received: chemotherapy

Prior chemotherapy

Cannot have received: surgery

Exception: except diagnostic

Prior surgery (except diagnostic) to primary tumor or nodes

Lab requirements

Blood counts

leucocyte count ≥4000/μL, hemoglobin ≥90g/L, platelet count ≥100000/μL

Kidney function

creatinine clearance ≥60 ml/min

Liver function

ALT, AST <1.5×ULN; ALP ≤2.5×ULN; bilirubin ≤ULN

Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count ≥100000/μL. Normal liver function test: ALT, AST <1.5×ULN; ALP ≤2.5×ULN, and bilirubin ≤ULN. Adequate renal function: creatinine clearance ≥60 ml/min.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT03919552 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage T3-4NX or TXN2-3 is required.

Is there an age limit?

Yes. Patients must be 64 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify